Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

February 28, 2013

Conditions
Shiga Toxin Producing Bacterial Infection
Interventions
DRUG

cαStx1/cαStx2

cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care

DRUG

Placebo

Placebo administered over 1 hour + standard of care

Trial Locations (11)

Unknown

Bahía Blanca

Buenos Aires

Córdoba

La Plata

Mendoza

Paraná

San Miguel de Tucumán

Concepción

Santiago

Valparaíso

Lima

Sponsors
All Listed Sponsors
collaborator

LFB Biotechnologies, SAS

UNKNOWN

lead

Thallion Pharmaceuticals

INDUSTRY